UNIVERSITY OF CALIFORNIA, DAVIS
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1905-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ucdavis.edu
Impact of Consumption of Orange-fleshed Sweet Potatoes on the Vitamin A Status of Bangladeshi Women of Reproductive Age
Not Applicable
Completed
- Conditions
- Vitamin A Deficiency
- Interventions
- Other: White-fleshed sweet potatoesOther: WFSP and capsule of retinyl palmitateOther: Orange-fleshed sweet potatoes (boiled)Other: Orange-fleshed sweet potatoes (fried)
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 130
- Registration Number
- NCT00453648
Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation
Phase 2
Completed
- Conditions
- Type 1 Diabetes
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2007-03-01
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 50
- Registration Number
- NCT00441844
- Locations
- 🇺🇸
UCDavis Medical Center, Sacramento, California, United States
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 64
- Registration Number
- NCT00408499
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
Phase 2
Withdrawn
- Conditions
- Metastatic CancerColorectal Cancer
- Interventions
- Biological: bevacizumabProcedure: conventional surgeryProcedure: neoadjuvant therapyProcedure: radiofrequency ablation
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- University of California, Davis
- Registration Number
- NCT00408772
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Phase 1
Completed
- Conditions
- Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 81
- Registration Number
- NCT00390429
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Phase 1
Completed
- Conditions
- Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 27
- Registration Number
- NCT00389805
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Genetic: comparative genomic hybridizationGenetic: cytogenetic analysisGenetic: gene expression analysisGenetic: mutation analysisGenetic: polymerase chain reactionGenetic: polymorphism analysisGenetic: proteomic profilingGenetic: reverse transcriptase-polymerase chain reactionOther: immunohistochemistry staining methodOther: laboratory biomarker analysis
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 22
- Registration Number
- NCT00389922
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol SpecificLong-term Effects Secondary to Cancer Therapy in ChildrenPoor Performance StatusBrain and Central Nervous System TumorsCognitive/Functional EffectsLong-term Effects Secondary to Cancer Therapy in Adults
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 30
- Registration Number
- NCT00389584
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 80
- Registration Number
- NCT00387660
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ
Not Applicable
Completed
- Conditions
- Breast Cancer
- Interventions
- Procedure: conventional surgeryProcedure: neoadjuvant therapyProcedure: radiofrequency ablation
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2010-03-29
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 15
- Registration Number
- NCT00388115
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
© Copyright 2025. All Rights Reserved by MedPath